TP53 and cancer: To study how TAZ activation drives aggressive GBM progression, we devised a TAZ-driven xenograft GBM mouse model by stably expressing a constitutively active TAZ mutant (TAZ4SA)26 in a commonly used LN229 human GBM cell line (Supplementary Fig. 1a), which contains a P98L missense mutation in p53 (Cancer Cell Line Encyclopedia).